PharmAla Biotech Logo 800 x 422.png
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
January 25, 2024 12:09 ET | PharmAla Biotech
PharmAla granted a Health Canada Controlled Drugs and Substances Dealer's License
PharmAla Biotech Logo 800 x 422.png
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
January 24, 2024 09:35 ET | PharmAla Biotech
PharmAla recieved a new OTCQB ticker, MDXXF.
PharmAla Biotech Logo 800 x 422.png
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
January 08, 2024 08:55 ET | PharmAla Biotech
PharmAla announces that its novel P1 molecule has been accepted by USPTO to its accelerated "Patent Prosecution Highway"
PharmAla Biotech Logo 800 x 422.png
PharmAla Files Audited Financials for Year Ending August 31, 2023
December 29, 2023 16:00 ET | PharmAla Biotech
PharmAla releases audited year-end financials for the period ended August 31st.
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules
November 15, 2023 08:55 ET | PharmAla Biotech
PharmAla Biotech contracted with Filament Health to manufacture a second batch of MDMA capsules; manufacturing is complete and shipped to clients.
PharmAla Biotech Logo 800 x 422.png
World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment
November 09, 2023 08:55 ET | PharmAla Biotech
PharmAla partners with Heroic Hearts Canada and the University of Calgary to launch the world's first observational rial into MDMA's real-world efficacy
PharmAla Biotech Logo 800 x 422.png
PharmAla Partners with Clariti Strategic Advisors™
November 08, 2023 08:55 ET | PharmAla Biotech
PharmAla signs long-term partnership with Clariti Strategic Partners as its investment banking and advisory firm
PharmAla Biotech Logo 800 x 422.png
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
November 07, 2023 08:55 ET | PharmAla Biotech
PharmAla completes the historic first shipment of MDMA and Psilocybin to its Australian Joint Venture, Cortexa, for use in commercial patient treatments
PharmAla Biotech Logo 800 x 422.png
PharmAla Receives First Office Action for PharmAla-1 PCT Filing
September 25, 2023 08:55 ET | PharmAla Biotech
PharmAla has recieved a positive First Office Action on its novel P-1 Molecule from the Patent Cooperation Treaty
PharmAla Biotech Logo 800 x 422.png
PharmAla Begins Trading on OTCQB
September 06, 2023 08:55 ET | PharmAla Biotech
VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:PMBHF), a biotechnology company focused on the...